<table>
<thead>
<tr>
<th>No oxygen support (early COVID-19, but at high risk of progression)</th>
<th>Low-flow oxygen (COVID-19 pneumonia)</th>
<th>High-flow oxygen/CPAP/mechanical ventilation (COVID-19 pneumonia)</th>
</tr>
</thead>
</table>
| **Recommended** | **Neutralising monoclonal antibodies** *(See policy for more details)*  
- Aged 12 or over, and weight 40 kg or over, and  
- who are not in hospital | **Corticosteroids** *(dexamethasone, or either hydrocortisone or prednisolone)* | **Tocilizumab** *(See policy for more details)*  
If C-reactive protein is 75 mg/litre or more |
| Benefits outweigh harms for almost everyone. All or nearly all informed people would likely want this option. | | **Tocilizumab** *(See policy for more details)*  
If within 48 hours of starting this level of support |
| **Neutralising monoclonal antibodies** *(See policy for more details)*  
- Aged 12 or over, and weight 40 kg or over, and  
- who are not in hospital | **Baricitinib**  
Adults | **Baricitinib**  
Adults |
| **Conditional for** | **Nirmatrelvir and ritonavir** *(See policy for more details)*  
- Aged 18 or over, and  
- within 5 days of symptom onset | **Low molecular weight heparin** *(standard prophylactic dose)*  
Adults or young people, if within 14 hours of admission and no increased bleeding risk | **Sarilumab** *(See policy for more details)*  
- If tocilizumab unavailable or cannot be used, and  
- C-reactive protein level is 75 mg/litre or more |
| Benefits outweigh harms for the majority, but not for all. The majority of informed people would likely want this option. | **Remdesivir** *(See policy for more details)*  
- Aged 12 or over, and weight 40 kg or over, and  
- within 7 days of symptom onset | **Sarilumab** *(See policy for more details)*  
- If tocilizumab unavailable or cannot be used, and  
- within 48 hours of starting this level of support (see policy) |
| **Remdesivir** *(See policy for more details)*  
- Aged 12 or over, and weight 40 kg or over, and  
- within 7 days of symptom onset | **Molnupiravir** *(See policy for more details)*  
- Aged 18 or over, and  
- within 5 days of symptom onset | **Baricitinib**  
Children and young people aged 2 to 18 |
| **Molnupiravir** *(See policy for more details)*  
- Aged 18 or over, and  
- within 5 days of symptom onset | **Remdesivir**  
Aged 12 or over and weight 40 kg or over | **Remdesivir**  
Adults or young people, if no increased bleeding risk |
| **Low molecular weight heparin** *(treatment dose)*  
Adults or young people, if no increased bleeding risk | **Low molecular weight heparin** *(treatment dose)*  
Adults or young people, if no increased bleeding risk | **Casirivimab and imdevimab**  
- If no detectable SARS-CoV-2 antibodies (seronegative), and aged 12 or over, and  
- infection known to be caused by variant susceptible to casirivimab and imdevimab |
Managing COVID 19: treatments (May 2022 v24.0)

No oxygen support (early COVID-19, but at high risk of progression)

- Tocilizumab
  For children and young people aged 1 year or over who have severe COVID-19 or paediatric inflammatory multisystem syndrome

- Budesonide (inhaled)

Low-flow oxygen (COVID-19 pneumonia)

- Remdesivir
  Low molecular weight heparin (intermediate or treatment dose)
  For adults or young people, if no increased bleeding risk

- Ivermectin

High-flow oxygen/CPAP/mechanical ventilation (COVID-19 pneumonia)

- Casirivimab and imdevimab
  If infection known to be caused by omicron variant, or any other variant not susceptible to casirivimab and imdevimab

- Molnupiravir
  For children and young people aged under 18, or pregnant women

- Azithromycin

- Colchicine

- Doxycycline

- Corticosteroids

Only in research

The option should only be available as part of a clinical trial.

- Tocilizumab
- Budesonide (inhaled)
- Remdesivir
- Low molecular weight heparin (intermediate or treatment dose)
- Ivermectin
- Casirivimab and imdevimab
- Molnupiravir
- Azithromycin
- Colchicine
- Doxycycline
- Corticosteroids

Not recommended

All or nearly all informed people would likely decline this option.

- Tocilizumab
- Budesonide (inhaled)
- Remdesivir
- Low molecular weight heparin (intermediate or treatment dose)
- Ivermectin
- Casirivimab and imdevimab
- Molnupiravir
- Azithromycin
- Colchicine
- Doxycycline
- Corticosteroids